Stemline Therapeutics to Present SL-401 Updated Data from Stage 1d 2 of Ongoing Pivotal Phase 2 BPDCN Trial at EHA Meeting; Says Remains On Track to Provide  Update on BPDCN Patients Enrolled in Stage 3 of Phase 2 Pivotal Trial in H2 of This Year